Cuevas-Orta E, Abud-Mendoza C

Idioma: Español
Referencias bibliográficas: 18
Paginas: 455-456
Archivo PDF: 96.03 Kb.

FRAGMENTO

El artículo de Rojas-Serrano, Mejía y Gaxiola1 invita a la reflexión y a tener presentes algunos puntos de vista paralelos y otros que pudieran ampliar el horizonte.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rojas-Serrano J, Mejía M, Gaxiola M. Enfermedad pulmonar intersticial asociada a la artritis reumatoide. Rev Invest Clin 2012; 64: 558-66.

2. Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008; 35: 1513-21.

3. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Airways abnormalities and rheumatoid arthritis–related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012; 64: 1756-61.

4. Nielsen SF, Bojesen SE,Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012; 345: e5244. Doi: 10.1136/bmj.e5244

5. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006; 65: 535-7.

6. Pini A, Viappiani S, Bolla M, Masini E, Bani D. Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor. J Pharmacol Exp Ther 2012; 341: 493-9.

7. Ohbayashi M, Suzuki M, Yashiro Y, Fukuwaka S, Yasuda M, Kohyama N, Kobayashi Y, et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. J Toxicol Sci 2010; 35: 653-61.

8. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011; 17: 362-7.

9. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012; 51: 653-62.

10. Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013. pii: S1568-9972(13)00075-X. Doi: 10.1016/ j.autrev.2013.05.001 [Epub ahead of print].

11. Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol 2012; 5: 219-27.

12. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013; 25: 56-64.

13. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012; 91: 30-43.

14. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011; 70: 1401-06

15. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 21(379): 244-9.

16. Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LT, Askling J. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308: 1350-6.

17. Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013; 25: 317-24.

18. Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 2011; 63: 352-8.